Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification.
Gynecol Oncol Rep
; 54: 101426, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38881561
ABSTRACT
â¢ESR1 gene amplification occurs in 7% of uterine carcinosarcoma.â¢The presence of ESR1 gene amplification in recurrent uterine carcinosarcoma may be targeted by aromatase inhibitors.â¢ESR1 gene amplification may be identified through immunohistochemical staining for estrogen receptor followed by fluorescence in situ hybridization or tumor targeted gene sequencing.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article